aespironics specializes in pulmonary drug-delivery via novel patented dry powder inhaler (DPIs) devices. Many injectable drugs are being reformulated for pulmonary delivery, and the leading method of pulmonary delivery is the use of dry powder inhalers (DPIs). The company is developing a series of products based on its proprietary breath driven scraping / brushing technology.

The company's lead product is a credit-card shaped disposable inhaler, which delivers high-performance in a convenient shape and at a low cost.

The investors in aespironics include a leading Israeli VC company, Maayan Ventures and
the Chief Scientist's Office of the Israeli Ministry of Trade and Industry.

The company has assembled an international team of technology experts, and seeks collaborations with drug companies in matching their newly formulated dry powders to the company's inhaler technology.